

# Developing Metal Complexes for Captopril Quantification in Tablets Using Potentiometric and Conductometric Methods

Badriah Saad Al-Farhan, Anas Alfarsi, Laila H. Abdel-Rahman, Ahmed H. Naggar, and Othman A. Farghaly\*



Cite This: *ACS Omega* 2023, 8, 2773–2779




Read Online

ACCESS |

Metrics & More

Article Recommendations

**ABSTRACT:** Potentiometric and conductometric methods were successfully applied to elucidate the interaction of 10 ions, viz.,  $\text{Cr}^{3+}$ ,  $\text{Fe}^{3+}$ ,  $\text{La}^{3+}$ ,  $\text{Th}^{4+}$ ,  $\text{Co}^{2+}$ ,  $\text{Mn}^{2+}$ ,  $\text{Pd}^{2+}$ ,  $\text{Sr}^{2+}$ ,  $\text{Ti}^{2+}$ , and  $\text{Zr}^{2+}$ , with the antihypertensive drug captopril (CAP) and its role to determine CAP in pure powder and tablet forms. The ionization constant of CAP and the generated complexes' stability constants ( $\log K$ ) were evaluated using potentiometric and conductometric methods at  $25 \pm 0.1$  °C and 0.05 M ionic strength ( $I$ ) of  $\text{NaNO}_3$  aqueous solution, and CAP was then determined in pure powder and tablet forms. Complexes having metal:ligand ratios of 1:1, 1:2, and/or 1:3 were produced, regardless of the type of the ligand or metal ions. Both the suggested potentiometric and conductometric procedures were utilized to confirm the stoichiometry of the M–CAP binary complexes formed. These two different techniques were utilized successfully to determine CAP in pure powder and tablet forms. Using the standard addition method (SAM) based on the Gran plot, CAP was satisfactorily determined throughout the concentration range of 0.83–13.04 mg/mL ( $\text{SD} = 0.20$ ,  $R = 0.9986$  ( $n = 5$ )), with a detection limit of 0.64 mg/mL ( $\text{SD} = 0.20$ ,  $R = 0.9986$  ( $n = 5$ )). In the presence of common tablet excipients, no interferences were observed. The percentage of CAP recovered from various dosage formulations (tablets) varied from 95.88 to 99.92%.



## 1. INTRODUCTION

Captopril (CAP), also known chemically as [2S]-N-[3-mercapto-2-methylpropionyl]-L-proline, is a broadly utilized drug for the treatment of high blood pressure, diabetic nephropathy, congestive heart seizure, and the preservation of kidney damage.<sup>1,2</sup> In order to investigate the presence of CAP in pharmaceuticals, numerous analytical procedures have been postulated. CAP was determined using chromatography,<sup>3–6</sup> fluorometry,<sup>7–9</sup> UV–visible spectroscopy,<sup>10,11</sup> chemiluminescence,<sup>12</sup> and voltammetric techniques.<sup>13–17</sup> Although these analytical strategies are highly sensitive and accurate, they are costly, time-consuming, and require complex procedures for sample preparation and analysis protocols.

The use of potentiometric and conductometric methods to analyze the binary and ternary complexes formed between metals and biological and pharmacological compounds has attracted a lot of interest as electrochemical methods.<sup>18–24</sup> CAP was previously determined using potentiometric<sup>25–28</sup> and conductometric<sup>29–32</sup> methods. The potentiometric assessment of complex formation among both stimulants and metal ions gives a clear overview of how interactions between drugs and metals may affect medication delivery to target areas.<sup>33,34</sup> In biological fluids, the presence of certain ions is thought to have

a major impact on the pharmacological actions of some chemical substances.<sup>35</sup>

As an analytical application of potentiometric studies, the equivalence point of the produced titration curves was identified using the Gran plot.<sup>36</sup> Sundry Gran plot applications have been published in the literature.<sup>37–44</sup> The goal of this work was to create a potentiometric process for assessing CAP in tablets directly using a Gran plot which was designed using data from a potentiometric investigation of the complexation equilibrium of CAP with various metal ions, especially  $\text{Cr}^{3+}$ ,  $\text{Fe}^{3+}$ ,  $\text{La}^{3+}$ ,  $\text{Th}^{4+}$ ,  $\text{Co}^{2+}$ ,  $\text{Mn}^{2+}$ ,  $\text{Pd}^{2+}$ ,  $\text{Sr}^{2+}$ ,  $\text{Ti}^{2+}$ , and  $\text{Zr}^{2+}$ .

## 2. EXPERIMENTAL SECTION

**2.1. Reagents and Instruments.** Sigma (St Louis, MO, USA) provided captopril (CAP), and NaOH (BDH) was used as earned. Most other ionic species solutions ( $\text{NO}_3^-$  and  $\text{Cl}^-$

Received: November 21, 2022

Accepted: December 20, 2022

Published: January 2, 2023



salts) were of highest purity, and they were used exactly as acquired from the manufacturer (BDH, UK, Geneva, or India).

**Pharmaceutical formulations:** captopril tablets (25 and 50 mg) manufactured by Sedico Pharmaceutical Co., 6th of October City, Egypt. Deptopril was bought from Micro Labs Ltd., India. Epsitron was purchased from Remedica Ltd., Limassol, Cyprus, Europe. Captopril was manufactured by HEXALAG83607, Holzkirchen, Germany. Capritin was obtained from Laboratorios Atral, S.A. Lisbon, Portugal. All these pharmaceutical samples were used for CAP determination.

VWR Scientific Products Model 2000, USA, was used to gather all the pH readings. Standard buffer pH values of 4.01, 7.00, and 9.00 were used to calibrate the combined glass electrode. A conductivity meter model 4320 Jenway with an immersion cell was used to conductometrically titrate the samples. In both pH and conductometric titration curves, the solution was kept under constant agitation at a temperature of  $25 \pm 0.1$  °C.

**2.2. Methods.** **2.2.1. Metal Complexes of CAP.** The dissociation constant of CAP as well as the formation constant of its various complexes with the studied ions in aqueous solution was calculated using the Calvin–Bjerrum approach, as described by Irving and Rossotti.<sup>37</sup> At  $25 \pm 0.1$  °C, the following solutions were potentiometrically titrated with 0.1 M standard CO<sub>2</sub>-free NaOH solution (which was standardized against potassium hydrogen phthalate):

- 0.005 M HNO<sub>3</sub> + 0.045 M NaNO<sub>3</sub> (for cell calibration).
- Solution (a) + 0.001 M CAP (for the purpose of determining the CAP protonation constants).
- Solution (b) + 0.001 M metal ions solutions (for the log *K* determination of metal ion–CAP binary complexes (M–CAP))

With the addition of dual-distilled water, the entire volume was maintained at a constant level at 50 mL. Titrations were carried out in aqueous solution at  $25 \pm 0.1$  °C with various values of *I* = 0.05, 0.15, and 0.25 M NaNO<sub>3</sub>.

Conductometric titrations were carried out at  $25 \pm 0.1$  °C by combining 25 mL of  $1 \times 10^{-3}$  M of each ion with  $1 \times 10^{-2}$  M of CAP (in 0.5 mL increments). By multiplying the specific conductance values by  $((25 + V))/25$ , where *V* is the volume of the titrant delivered, the dilution effect is corrected.

**2.2.2. Determination of CAP.** **2.2.2.1. Pure Form.** A stock solution (25 mL) of CAP ( $1 \times 10^{-2}$  M) (*I* is adapted to 0.5 M with NaNO<sub>3</sub>) was provided by diluting the actual stock solution with double-distilled water. Regarding this, 15 mL of CAP solution was potentiometrically and conductometrically treated with few drops of NaOH solution (*I* = 0.1 M) in a thermostated glass cell ( $25 \pm 0.1$  °C).

**2.2.2.2. Tablet Form.** Ten tablets were weighed and then finely pulverized and homogenized to obtain the average tablet weight. A portion of the powder that contains about 21.7 mg of CAP was accurately weighed and added in 10 mL of double-distilled water. The derived samples were filtered, and their ionic strength was reduced to 0.5 M using NaNO<sub>3</sub>. Finally, in a 25 mL flask, a portion of this solution was diluted in double-distilled water and analyzed for the pure form of CAP, as previously stated. Using a standard calibration curve, the quantity of CAP per tablet was calculated.


**2.2.3. Statistical Analysis.** All statistics, stoichiometry constant, and log *K* were illustrated and calculated using Microsoft Excel. For CAP determination, the Gran plot was

constructed, and LOD, LOQ, and SD were calculated using SAM. Previously, Microsoft Excel and SAM were successfully applied for the same purpose.<sup>18,39–41</sup>

### 3. RESULTS

#### 3.1. Formation Constants of CAP Complexes.

**3.1.1. Proton–Ligand Stability Constants of CAP.** CAP was potentiometrically titrated in the presence of 0.01 M HNO<sub>3</sub>. At *I* = 0.05, 0.15, and 0.25 M NaNO<sub>3</sub> at  $25 \pm 0.1$  °C, using CO<sub>2</sub>-free NaOH as a titrant, the protonation constant of CAP and log *K* of CAP complexes formed with some metal ions were tabulated (Figure 1).




**Figure 1.** Potentiometric titration curves of CAP at 0.05 M NaNO<sub>3</sub> and  $25 \pm 0.1$  °C: (a) 0.01 M HNO<sub>3</sub>, (b) a + 0.001 M CAP, (c) b + 0.001 M Th<sup>4+</sup>, (d) b + 0.001 M Co<sup>2+</sup>, (e) b + 0.001 M Zr<sup>2+</sup>, (f) b + 0.001 M Ti<sup>2+</sup>, and (g) b + 0.001 M Sr<sup>2+</sup>.

The proton–ligand formation constants will be determined by charting  $\bar{n}A$  against pH, according to Irving and Rossotti<sup>45</sup> (for the potentiometric titration curves a and b). As shown in eq 1, the average number of attached protons per ligand,  $\bar{n}A$ , was calculated at various pH values:

$$\bar{n}A = Y + \frac{(V_1 - V_2)(N^\circ + E^\circ)}{(V^\circ + V_1)T_L^\circ} \quad (1)$$

where *V*<sub>1</sub> and *V*<sub>2</sub> are the alkali portions required to achieve the same pH in inorganic acid (HNO<sub>3</sub>) and (HNO<sub>3</sub> + CAP) solutions, respectively. *T*<sub>L</sub><sup>°</sup> represents the total concentration of CAP, *N*<sup>°</sup> represents the concentration of NaOH solution (0.1 M), and *E*<sup>°</sup> represents the preliminary concentration of free HNO<sub>3</sub> in the titrated solution. The following diagram depicts the reaction mechanism:




**3.1.2. Determination of Formation Constants of Metal–CAP Complexes.** The pH-metric titration of 10 metal salts, Fe<sup>3+</sup>, Cr<sup>3+</sup>, La<sup>2+</sup>, Th<sup>4+</sup>, Co<sup>2+</sup>, Mn<sup>2+</sup>, Pd<sup>2+</sup>, Ti<sup>2+</sup>, Sr<sup>2+</sup>, and Zr<sup>2+</sup>, was performed and researched using a potentiometric method to elucidate their interaction with CAP. The titration curves of the M–CAP solutions (from c to g) differ and are well separated from curve b, which is related to free CAP (Figure

1). Complexation is responsible for the replacement of the H<sup>+</sup> ion. The Irving and Rossotti equations<sup>45</sup> were utilized to calculate the  $\bar{n}$  (the average number of CAP molecules for every metal ion) and pL (free-ligand exponent) values from these titration curves.

$$\bar{n} = \frac{(V_3 - V_2)(N^\circ + E^\circ)}{(V^\circ + V_2)\bar{n}HT_cM^\circ} \quad (3)$$

$$pL = \log \left[ \frac{1 + \beta_1[H^+] + \beta_2[H^+]^2}{(T_cL^\circ - \bar{n}T_cM^\circ)} \times \frac{V^\circ + V_3}{V^\circ} \right] \quad (4)$$

where  $V_2$  and  $V_3$  are the alkali quantities necessary to achieve the very same pH for free acid and free acid + CAP + metal solutions, in both.  $V^\circ$  denotes the original volume of the mixtures (50 mL), and  $T_cM^\circ$  indicates the total metal content in the solution. Metal complexation equilibria formation curves were derived from charting the  $\bar{n}$  values versus the relevant pL values (Figure 2).



**Figure 2.** Illustrative formation curves of binary metal ion complexes with CAP at 0.05 M NaNO<sub>3</sub> and 25 ± 0.1 °C: (a) Ti<sup>2+</sup>, (b) Zr<sup>2+</sup>, (c) Sr<sup>2+</sup>, (d) Mn<sup>2+</sup>, and (e) La<sup>2+</sup>.

Table 1 shows the log  $K$  values of metal ion complexes which were calculated in 0.05 M NaNO<sub>3</sub> using the half-integral

**Table 1. Protonation Constants of CAP and log  $K$  of Metal Ion Complexes at 0.05 M NaNO<sub>3</sub> and 25 ± 0.1 °C**


central ion	log $K_1$ (M:L) <sup>a</sup>	log $K_2$ (M:L) <sup>a</sup>	log $K_3$ (M:L) <sup>a</sup>
H <sup>+</sup>	9.7 (1:1)	3.7 (1:2)	
Fe <sup>3+</sup>	7.9 (1:1)	5.55 (1:2)	
Pb <sup>2+</sup>	6.39 (1:1)	5.54 (1:2)	4.22 (1:3)
Co <sup>2+</sup>	7.73 (1:1)		
Cr <sup>3+</sup>	7.94 (1:1)	5.94 (1:2)	
Th <sup>4+</sup>	6.96 (1:1)	5.7 (1:2)	4.38 (1:3)
Zr <sup>2+</sup>	7.97 (1:1)		
Mn <sup>2+</sup>	6.99 (1:1)	5.06 (1:2)	
La <sup>2+</sup>	6.5 (1:1)		
Ti <sup>2+</sup>	6.76 (1:1)		
Sr <sup>2+</sup>	6.16 (1:1)	5.065 (1:2)	

<sup>a</sup>Potentiometric and conductometric methods were used to calculate these ratios.

method.<sup>45</sup> From the tabulated formation constant data, over the studied pH range, we can ensure the presence of the M–CAP complex (1:1) (metal:CAP) with some metal ions, viz., Co<sup>2+</sup>, Zr<sup>2+</sup>, La<sup>2+</sup>, and Ti<sup>2+</sup>, while the formation of other M–CAP complexes is disrupted by metal ion precipitation and hydrolysis. As a result, the newly discovered pH data would be

useless in computing values. Furthermore, because the pH observations at this stage displayed an unsteady drift, these data cannot be considered to be in equilibrium. Moreover, some ions, such as Sr<sup>2+</sup>, Mn<sup>2+</sup>, Fe<sup>3+</sup>, and Cr<sup>3+</sup>, create two forms of M–CAP complexes (1:1) and (1:2) (metal:CAP), whereas other ions, such as Pb<sup>2+</sup> and Th<sup>4+</sup>, produce three types of M–CAP complexes (1:1), (1:2), and (1:3) at the investigated  $I$  values. It could also be owing to the CAP concentration,  $I$ , or the metal ion nature.


As expected, log  $K$  of the various complexes produced between CAP and the inspected metal ions in this research follows the Irving–Williams order<sup>46</sup> for (1:1) (metal:CAP) at  $I = 0.05$  M NaNO<sub>3</sub>:



The effect of  $I$  alteration on log  $K$  of M–CAP complexes using various metal ions, Cr<sup>3+</sup>, Fe<sup>3+</sup>, Co<sup>2+</sup>, Th<sup>4+</sup>, and Pb<sup>2+</sup>, was investigated at 25 ± 0.1 °C using NaNO<sub>3</sub> at  $I = 0.05, 0.15,$  and 0.25 M. We can conclude that a diminish occurred in log  $K$  of the M–CAP complexes (1:1) by plotting the correlation between the investigated  $I$  and log  $K_1^H$ .

**3.2. Conductometric Results for the Metal Complexes of CAP.** The many forms of chelate complexes produced between Sr<sup>2+</sup>, Ti<sup>2+</sup>, La<sup>2+</sup>, Fe<sup>3+</sup>, and Th<sup>4+</sup> and CAP were traced using the conductivity data in this investigation. The recorded values of specific conductance were plotted as a function of the added volumes of CAP in a conductometric titration. The relationships have breaks that are clearly defined which correspond to the stoichiometric (M–CAP) complex ratios (1:1), (1:2), and/or (1:3). These findings are comparable with those acquired using the potentiometric process (Table 1).


**3.3. Species Distribution Diagrams of CAP Complexes.** Figure 3 shows that the main varieties of CAP in the



**Figure 3.** Ionic equilibria of CAP in diverse values of pH's.

pH range of 2.0–5.8 are the  $\alpha^0 = \text{H}_2\text{L}$  species, whereas the main species in the pH range of 6.0–7.4 are the  $\alpha_1 = \text{HL}^-$  species. Furthermore, the  $\alpha_2 = \text{L}^{2-}$  are the dominant species in the pH levels of 7.8–11.2. Mole fractions of  $\alpha_{ML}$  and  $\alpha_{ML2}$  can be determined from the potentiometric data using the obtained log  $K$  for ML complexes and the initial concentrations of metal ions and ligands.<sup>47</sup> Figure 3 depicts the species distribution curves as a function of pH. Plotting  $\alpha$  ( $\alpha =$  mole fraction of the species) versus pH values under consideration can produce all of these curves.

The distribution curves of the M–CAP complexes formed can be represented in Figure 4. These curves show that complexation begins at pH = 4.6 for Co<sup>2+</sup>, Zr<sup>2+</sup>, and Th<sup>4+</sup>; 4.2,



**Figure 4.** Ionic equilibria of La–CAP complexes in diverse values of pH's.

4.4, 4.45, 4.5, 4.62, 4.47, and 4.64 for  $\text{Pb}^{2+}$ ,  $\text{La}^{2+}$ ,  $\text{Sr}^{2+}$ ,  $\text{Mn}^{2+}$ ,  $\text{Ti}^{2+}$ ,  $\text{Fe}^{3+}$ , and  $\text{Cr}^{3+}$  complexes, respectively.

The most significant difference between pH 7.2 and 11.8 is the rise in  $\text{ML}_2$  concentration accompanied by a decline in ML. Beyond this pH range, a significant amount of  $\text{M}^{2+}$  ions persist as ML and  $\text{ML}_2$  species, which grow in concentration when the pH of the solution rises. This illustrates that the ML species have a much more sustainable solution than  $\text{ML}_2$ . This attitude is aware of the values of the chelates'  $\log K$  (Table 1). It is worthy to note that the ML varieties are prominent in  $\text{Sr}^{2+}$  over the pH range of 7.0–9.2, with no significant  $\text{ML}_2$  species of  $\text{Co}^{2+}$ ,  $\text{Fe}^{3+}$ , and  $\text{Th}^{4+}$ , however, at high pH values.


**3.4. Effect of Ionic Strength on Pure CAP Determination.** In the presence of  $1 \times 10^{-2}$  M CAP, the effect of  $I$  alteration on the proposed potentiometric and conductometric procedures for CAP determination was studied under optimized conditions. This study was accomplished over a concentration range of 0.05–1.5 M  $\text{NaNO}_3$ . The obtained results show that the calculated percentage recovery was close to 100% at  $I = 0.5$  M  $\text{NaNO}_3$ .

**3.5. Determination of CAP in Pure Form.** The suggested methods for determining pure CAP in  $\text{NaNO}_3$  were successfully implemented ( $I = 0.5$  M) at  $25 \pm 0.1$  °C. Recovery percentages ranging from 95.69 to 99.92% of CAP were obtained, with standard deviations (SD) of 0.56–0.78% ( $n = 5$ ) at 95% confidence level, respectively. The accuracy and precision of the procedures are evidenced by these outcomes.

The detection and quantification limits were computed as  $3\sigma/b$  and  $10\sigma/b$ , respectively, where  $b$  is the slope, and  $\sigma$  is the intercept SD.<sup>18</sup> It can be seen that CAP can be detected at 0.64 mg/mL (SD = 0.20,  $R = 0.9992$  ( $n = 5$ )). The calculated correlation coefficients are quite similar to those obtained earlier using various approaches for determining CAP like chromatography,<sup>3–6</sup> fluorometry,<sup>7–9</sup> UV–visible spectroscopy,<sup>10,11</sup> chemiluminescence,<sup>12</sup> voltammetry,<sup>13–17</sup> potentiometry,<sup>25–28</sup> and conductometry<sup>29–32</sup> methods. Using the proposed methods, CAP was determined successfully over a concentration range from 0.83 to 13.04 mg/mL (Figure 5).

**3.6. Interferences.** The impact of some additives used as excipients, such as D(+) lactose monohydrate and NaCl, was explored at least 100 times in a concentration range greater than that of pure CAP to assess the potential analytical applications of the explored methods to drug quality assurance.

**3.7. Analytical Applications.** Figure 6a depicts the curve for a typical potentiometric titration of capritin (50 mg) as an example. Variations at the titration end point were evident enough in the suggested technique to yield potentiometric titration curves of adequate shape for highly repeatable end



**Figure 5.** Linearity range of pure CAP at  $I = 0.5$  M  $\text{NaNO}_3$ .

sensing. Figure 6b,c represents the first and second derivatives of the potentiometric curve for calculating CAP, including both.

The conductometric titration method has the advantages of being simple, accurate, and reproducible for pure and dosage forms. The methods were used to test various brands of CAP-containing tablets.

The recovery (%) and standard deviation (SD) for both the proposed potentiometric and conductometric methods were calculated and tabulated in Table 2 under optimal conditions and using SAM for five repetitive readings.


## 4. DISCUSSION

In accordance with the previously published literature,<sup>48,49</sup> our studies prove that CAP has two sites where the ligand has a great tendency to form M–CAP complexes: the first site is the deprotonation of the carboxyl group (COOH) and the second one is the proton dissociation in the thiol group (SH). These sites are displayed in Figure 7.

It is important to note that using potentiometric approaches to predict the formation composition of binuclear complex species is exceptionally hard. This is because the complexes formed at high pH levels, which are over the precipitation point for such systems. The electron-withdrawing nature of the six-membered chelate ring formed, on the other hand, may explain CAP's weak tendency to form binuclear complexes. Also, this phenomenon could be explained by the steric effect, which is induced by electrostatic dissonance among the protonated metal complex and the metal ion.

The calculation of the first and second proton dissociation constants of CAP ( $\log K_1^{\text{H}}$  and  $\log K_2^{\text{H}}$ , respectively) was completed by plotting  $\bar{n}\text{H}$  against pH at 0.05 M  $\text{NaNO}_3$ . Table 1 shows the titration results using solutions a and b. The values of  $\log K_1^{\text{H}}$  and  $\log K_2^{\text{H}}$  are the pH values corresponding to  $\bar{n}\text{H} = 0.5$  and 1.5, respectively.

In order to track the compounds in solution, conductometric experiments can be used. This method can be used to track the digits' fluctuation in the transition metal ions' ionic radii. Conductometric study, in general, is attributed to the difference in the electrical conductivities of a solution as a result of complexes. The ion concentration present, as well as their agility, assess these variations. The perceived increase in conductivity throughout the metal ion titration with CAP, which resulted in the formation of CAP complexes, clearly indicates the deliverance of high mobile  $\text{H}^+$  ions. Thus, modification can occur through the emergence of a covalent bond among a metal ion and a sulfur atom in a thiol group (SH), followed by hydrogen ion liberation.




**Figure 6.** Exemplary potentiometric titration curves of capritin (50 mg): (a) titration curve with only one inflection point, (b) first derivative of curve (a), and (c) second derivative of curve (a).

**Table 2. Recovery Data for CAP Determination in Different Dosage Forms by the Proposed Potentiometric and Conductometric Methods<sup>a</sup>**

dosage forms	drug dose added (mg)	found (mg)	recovery (%) ( $n = 5$ )	SD ( $n = 5$ )	confidence ( $n = 5$ ) $\alpha = 0.05$
captopril (USP)	25	24.98 (23.89)	99.92 (98.92)	0.40 (0.38)	0.35 (0.33)
deftopril	25	24.92 (23.94)	99.68 (97.92)	0.39 (0.35)	0.34 (0.30)
epsitron	25	24.88 (23.95)	99.52 (98.97)	0.46 (0.43)	0.40 (0.38)
captohexal	50	48.89 (47.98)	97.78 (95.98)	0.53 (0.51)	0.46 (0.43)
capritin	50	48.08 (47.98)	96.16 (95.96)	0.70 (0.65)	0.61 (0.57)
captopril (E.I.P.I.CO)	50	48.90 (47.95)	97.80 (95.88)	0.62 (0.57)	0.54 (0.50)

<sup>a</sup>Data in brackets ( ) are from the conductometric method.



**Figure 7.** CAP sites as ligands to form M–CAP complexes (ratio of 1:1 (M:CAP)).

In the case of species distribution curves, increasing the pH value decreases the metal ion concentration, whereas ML species tend to develop in the medium with a mildly acidic pH (pH 4.6–7.0). The values of  $\alpha_M$ ,  $\alpha_{ML}$ , and  $\alpha_{ML_2}$  in solution are primarily determined by the medium's pH. Complex hydrolysis could explain the decreases in the concentration of the  $\text{Co}^{2+}$ ,  $\text{Fe}^{3+}$ , and  $\text{Th}^{4+}$  complexes in alkaline media.

The absolute and relative values of the respective stepwise ionization constants<sup>45</sup> determine the growth of polyprotic acid titration curves. In theory, each labile hydrogen will have one inflection. However, for an inflection to be associated with an adequate variation in pH, the following conditions must be met: (i) the relationship between the respective ionization constants must be greater than  $10^4$ , and (ii) the corresponding ionization constant must not be that of a very weak acid.<sup>47</sup> CAP is a dibasic acid having  $\text{p}K_{a1} = 3.7$  (COOH group) and  $\text{p}K_{a2} = 9.8$  (SH group); the titration curve shows a noticeable inflection for the first equivalence point where the relationship of the first and second dissociation constants is  $\text{p}K_1 - \text{p}K_2 = 6.1$ . However, CAP is a very weak acid with regard to its second hydrogen. Therefore, its titration curve does not present an obvious inflection and can be used to determine the second equivalence point.

The normal potentiometric titration curve for CAP has only one inflection point. Adjustments at the titration end point were capable of creating potentiometric titration curves with sufficient configuration for a reliable and repeatable end

detection in the proposed method. Although CAP has previously been defined using various analytical techniques, the proposed technique for CAP detection is indeed described as easy, cost next to nothing, and sample preparation does not necessitate lengthy and laborious procedures. The time needed for the potentiometric analysis of pure CAP (after sample preparation) was 10 min/specimen.

For CAP determination using the proposed method, no interference was observed from the studied chemical excipients over the studied CAP concentration range. Good recoveries ( $n = 5$ ) were obtained for all pharmaceutical preparations, from 96.16 to 99.92% for the potentiometric method (SD = 0.39–0.70) and from 95.88 to 99.52% for the conductometric method (SD = 0.35–0.65), respectively. Both potentiometric and conductometric approaches produce results that are in good accord with those seen in the literature. Results for recovery studies for both methods are shown in Table 2.

## 5. CONCLUSIONS

The complexation reaction between CAP and several ions, viz,  $\text{Cr}^{3+}$ ,  $\text{Fe}^{3+}$ ,  $\text{La}^{2+}$ ,  $\text{Th}^{4+}$ ,  $\text{Co}^{2+}$ ,  $\text{Mn}^{2+}$ ,  $\text{Pd}^{2+}$ ,  $\text{Sr}^{2+}$ ,  $\text{Ti}^{2+}$ , and  $\text{Zr}^{2+}$ , followed either the potentiometric method or the conductometric method. The use of these methods allows for the identification of the formed complexes, determination of their log  $K$ , and distribution of species for CAP and its metal complexes at different pH values. Furthermore, as far as we are aware, we were the first to offer potentiometric and conductometric methods for determining CAP in pharmaceutical formulations, with recovery values ranging from 95.88 to 99.92%.

## AUTHOR INFORMATION

### Corresponding Author

Osman A. Farghaly – Department of Chemistry, Faculty of Science, Albaha University, Albaha 61008, Saudi Arabia; Chemistry Department, Faculty of Science, Al-Azhar


University, 71524 Assiut, Egypt; Email: othman15@yahoo.com

## Authors

**Badriah Saad Al-Farhan** – Chemistry Department, Faculty of Girls for Science, King Khalid University, Abha 61421, Saudi Arabia

**Anas Alfarsi** – Department of Chemistry, Faculty of Science, Albaha University, Albaha 61008, Saudi Arabia

**Laila H. Abdel-Rahman** – Chemistry Department, Faculty of Science, Sohag University, 82524 Sohag, Egypt

**Ahmed H. Naggar** – Department of Chemistry, College of Science and Arts, Jouf University, Al-Qurayyat 75911, Saudi Arabia; Chemistry Department, Faculty of Science, Al-Azhar University, 71524 Assiut, Egypt;  [orcid.org/0000-0001-5492-6114](https://orcid.org/0000-0001-5492-6114)

Complete contact information is available at: <https://pubs.acs.org/10.1021/acsomega.2c07455>

## Notes

The authors declare no competing financial interest.

## ACKNOWLEDGMENTS

The authors would like to express their heartfelt gratitude to the Chemistry Department, Faculty of Girls for Science, King Khalid University, Abha, Kingdom of Saudi Arabia, for their encouragement during this investigation.

## REFERENCES

- (1) Brunton, L.; Lazo, J.; Parker, K. *Goodman & Gilman's The Pharmacological Basis of Therapeutics*, 10th Ed.; McGraw-Hill: New York, USA, 2001.
- (2) Murphy, D. L.; Mitchell, P. B.; Potter, W. Z. Novel pharmacological approaches to the treatment of depression. In *Psychopharmacology: The fourth generation of progress*, Bloom, F. E.; Kupfer, D. J., Eds.; Raven Press: New York, USA, 1995.
- (3) Elzanfaly, E. S.; Merey, H. A. A liquid chromatography/tandem mass spectrometric method for determination of captopril in human plasma: Application to a bioequivalence study. *J. Appl. Pharm. Sci.* **2017**, *7*, 008–015.
- (4) Logoyda, L.; Piponski, M.; Kovalenko, S.; Dutchak, O.; Deneff, O.; Soroka, Y.; Pidruchna, S.; Popovych, D.; Susla, O. Method development for the quantitative determination of captopril from caco-2 cell monolayers by using LC–MS/MS. *Pharmacia* **2021**, *68*, 61–67.
- (5) Zammit, G.; Cassar, R.; Pace, M. Quantification of captopril using ultra high performance liquid chromatography. *arXiv:2107.09724*, DOI: [10.48550/arXiv.2107.09724](https://doi.org/10.48550/arXiv.2107.09724).
- (6) Pebriana, R. B.; Damayanti, O.; Agustini, Y. D.; Lukitaningsih, E.; Bestari, A. N. Validation of a high-performance liquid chromatographic method for the assay and dissolution of captopril in mucoadhesive tablet formulation. *J. Appl. Pharm. Sci.* **2021**, *11*, 066–074.
- (7) El-Didamony, A. M. Spectrofluorimetric determination of the hypertensive drug captopril based on its oxidation with cerium (IV). *J. Chin. Chem. Soc.* **2009**, *56*, 755–762.
- (8) Derayea, S. M.; Nagy, D. M.; Badr El-Din, K. M.; Attia, T. Z.; Samir, E.; Mohamed, A. A.; Hamad, A. A. Green innovative fluorescence approach for the feasible and reliable assay of thiol-containing drugs; captopril as a model. *RSC Adv.* **2022**, *12*, 17607–17616.
- (9) Chen, Y.; Chang, W.; Zhu, X.; Wang, R.; Tian, F. Fluorescence quenching and measurement of captopril in pharmaceuticals. *Indian J. Biochem. Biophys.* **2020**, *57*, 270–276.
- (10) Rodrigues, S. S. M.; Santos, J. L. M. Chemiluminometric determination of captopril in a multi-pumping flow system. *Talanta* **2012**, *96*, 210–215.
- (11) Moldovan, Z.; Badea, I. A.; Bunaciu, A. A.; Aboul-Enein, H. Y. Indirect spectrophotometric method for determination of captopril using Cr (VI) and diphenylcarbazine. *Quim. Nova* **2012**, *35*, 1668–1672.
- (12) Dawood, N. H.; Ali, N. H. Spectrophotometric determination of captopril in pharmaceutical formulations based on ion-pair reaction with the red congo. *J. Pharm. Neg. Res.* **2022**, *13*, 36–42.
- (13) Absalan, G.; Akhond, M.; Karimi, R.; Ramezani, A. M. Simultaneous determination of captopril and hydrochlorothiazide by using a carbon ionic liquid electrode modified with copper hydroxide nanoparticles. *Microchim. Acta* **2018**, *185*, 97.
- (14) Soomro, R. A.; Tunesi, M. M.; Karakus, S.; Kalwar, N. Highly sensitive electrochemical determination of captopril using CuO modified ITO electrode: the effect of in situ grown nanostructures over signal sensitivity. *RSC Adv.* **2017**, *7*, 19353–19362.
- (15) Górska, A.; Paczosa-Bator, B.; Szlóscarczyk, M.; Piech, R. Highly sensitive voltammetric determination of captopril on renewable amalgam film electrode. *Talanta* **2022**, *237*, No. 122937.
- (16) Shahbakhsh, M.; Hashemzadei, Z.; Narouie, S.; Shahbakhsh, Y.; Noroozifar, M. Gold nanoparticles/biphenol–biphenanthroquinone for ultra-trace voltammetric determination of captopril. *Electroanalysis* **2021**, *33*, 713–722.
- (17) Safaei, O.; Beitollahi, H.; Shishehboore, M. R.; Tajik, S.; Hosseinzadeh, R. Electrocatalytic determination of captopril using a carbon paste electrode modified with N-(ferrocenyl-methylidene)-fluorene-2-amine and graphene/ZnO nanocomposite. *J. Serb. Chem. Soc.* **2019**, *84*, 175–185.
- (18) Mohamed, H. A.; Wadood, H. M. A.; Farghaly, O. A. Potentiometric and spectrofluorimetric studies on complexation of tenoxicam with some metal ions. *J. Pharm. Biomed. Anal.* **2002**, *28*, 819–826.
- (19) Naggar, A. H.; Mauof, H. A.; Ekshiba, A. A.; Farghaly, O. A. Potentiometric and conductometric studies of binary and ternary complexes of sulphamethoxazole and glycine with metal ions. *Pharm. Chem. J.* **2016**, *3*, 125–137.
- (20) Al-Rashdi, A. A.; Naggar, A. H.; Farghaly, O. A.; Mauof, H. A.; Ekshiba, A. A. Potentiometric and conductometric studies of sulfathiazole:glycine binary and ternary complexes. *Int. J. Electrochem. Sci.* **2019**, *14*, 1132–1146.
- (21) Naggar, A. H.; Al-Saidi, H. M.; Farghaly, O. A.; Hassan, T. M.; Bortata, S. Z. M. Complexation equilibria of ambroxol hydrochloride in solution by potentiometric and conductometric methods. *Eur. J. Chem.* **2018**, *9*, 49–56.
- (22) Yousef, W. M.; Alenezi, K.; Naggar, A. H.; Hassan, T. M.; Bortata, S. Z.; Farghaly, O. A. Potentiometric and conductometric studies on complexes of folic acid with some metal ions. *Int. J. Electrochem. Sci.* **2017**, *12*, 1146–1156.
- (23) Tantawy, M. A.; Elshabasy, D. A.; Youssef, N. F.; Amer, S. M. Stability indicating potentiometric method for the determination of palonosetron HCl using two different sensors. *Sci. Rep.* **2022**, *12*, 12966.
- (24) Elgendy, K.; Elmosallamy, M. A. F.; Soltan, M. K.; Amin, A. S.; Elshaprawy, D. S. Novel potentiometric methods for the estimation of bisoprolol and alverine in pharmaceutical forms and human serum. *Rev. Anal. Chem.* **2021**, *40*, 127–135.
- (25) Ribeiro, P. R. S.; Santini, A. O.; Pezza, H. R.; Pezza, L. Potentiometric determination of captopril in pharmaceutical formulations. *Ecl. Quím.* **2003**, *28*, 39–44.
- (26) Mohamed, M. E.; Aboul-enein, H. Y.; Gad-kariem, E. A. Potentiometric and visual titrimetric methods for analysis of captopril and its pharmaceutical forms. *Anal. Lett.* **1983**, *16*, 45–55.
- (27) Moustafa, M. H.; Elgailani, I. E. H.; Gad-Elkareem, M. A. M. Potentiometric and spectrophotometric studies on the complexes of zinc (II) with captopril. *Int. J. Recent Sci. Res.* **2017**, *8*, 20186–20189.

- (28) Pimenta, A. M.; Araújo, A. N.; Montenegro, M. C. B. S. M. Sequential injection analysis of captopril based on colorimetric and potentiometric detection. *Anal. Chim. Acta* **2001**, *438*, 31–38.
- (29) Lourenção, B. C.; Marcolino-Junior, L. H.; Fatibello-Filho, O. Conductometric determination of captopril in pharmaceutical formulations using copper(II) sulphate as titrant. *Quim. Nova* **2008**, *31*, 349–352.
- (30) El Kerday, M. M. Conductometric determination of some pharmaceutically important thiol compounds in dosage forms. *Mansoura J. Pharm. Sci.* **1993**, *9*, 191–203.
- (31) Janegitz, B. C.; Suarez, W. T.; Fatibello-Filho, O.; Marcolino-Junior, L. H. Conductometric determination of N-acetylcysteine in pharmaceutical formulations using copper(II) sulphate as titrant. *Anal. Lett.* **2008**, *41*, 3264–3271.
- (32) Rizk, M. S.; Belal, F.; Eid, M. M. Conductometric determination of some pharmaceutically important thiol compounds in dosage forms. *Acta Pharm. Hung.* **1993**, *63*, 313–318.
- (33) Al-Farhan, B. S.; Gouda, G. A.; Farghaly, O. A.; El-Khalafawy, A. K. Potentiometric study of new schiff base complexes bearing morpholine in ethanol-water medium with some metal ions. *Int. J. Electrochem. Sci.* **2019**, *14*, 3350–3362.
- (34) Riccardi, L.; Genna, V.; De Vivo, M. Metal–ligand interactions in drug design. *Nat. Rev. Chem.* **2018**, *2*, 100–112.
- (35) Alhazmi, H. A.; Nasib, A. A. B.; Musleh, Y. A.; Hijri, K. Q.; Rehman, Z.; Khuwaja, G.; Al-Bratty, M.; Javed, S. A.; Arbab, I. A. Application of drug–metal ion interaction principle in conductometric determination of imatinib, sorafenib, gefitinib and bosutinib. *Open Chem.* **2020**, *18*, 798–807.
- (36) Gran, G. Determination of the equivalence point in potentiometric titrations. Part II. *Analyst* **1952**, *77*, 661–671.
- (37) Basavaiah, K.; Nagegowda, P.; Chandrashekar, U. Determination of tinidazole by potentiometry, spectrophotometry and high performance liquid chromatography. *Indian J. Chem. Technol.* **2005**, *12*, 273–280.
- (38) Aslan, N.; Erden, P. E.; Canel, E.; Zeybek, B.; Kiliç, E. Potentiometric determination of valsartan in a pharmaceutical preparation and its protonation constants. *Asian J. Chem.* **2010**, *22*, 4010–4016.
- (39) Farghaly, O. A.; Al-Saidi, H. M.; Naggar, A. H.; El-Mabrouk, I. M. Metal complexes and determination of nalidixic acid by potentiometric and conductometric methods. *Int. J. Electrochem. Sci.* **2017**, *12*, 9865–9881.
- (40) Al-Rashdi, A. A.; Naggar, A. H.; Farghaly, O. A.; Khouda, M. M.; Shafter, M. M. Potentiometric and conductometric determination of metal complexes of tenoxicam in different dosage forms. *Int. J. Pharm. Phytopharmacol. Res.* **2018**, *8*, 13–22.
- (41) Al-Farhan, B. S.; Naggar, A. H.; Farghaly, O. A. Potentiometric and conductometric study of complex formations between norfloxacin and some metal ions and norfloxacin determination in dosage forms. *Int. J. Electrochem. Sci.* **2018**, *13*, 8275–8294.
- (42) Polat, M. B.; Doğan, A.; Başçı, N. E. Spectrophotometry, potentiometry and HPLC in determination of acidity constant for cabergoline and tadalafil. *J. Res. Pharm.* **2019**, *23*, 177–186.
- (43) Budetić, M.; Samardžić, M.; Bubnjar, K.; Dandić, A.; Živković, P.; Széchenyi, A.; Kiss, L. A new sensor for direct potentiometric determination of thiabendazole in fruit peels using the Gran method. *Food Chem.* **2022**, *392*, No. 133290.
- (44) Guedens, W. J.; Reynders, M.; Vinckenroye, K. V.; Yperman, J.; Carleer, R. Monitoring the chloride concentration in international scheldt river basin district water using a low-cost multifunction data acquisition board. *Water* **2018**, *10*, 1025.
- (45) Irving, H.; Rossoti, H. S. Methods for computing successive stability constants from experimental formation curves. *J. Chem. Soc.* **1953**, 3397–3405.
- (46) Irving, H.; Williams, R. J. P. Order of stability of metal complexes. *Nature* **1948**, *162*, 746–747.
- (47) Beck, M. T. *Chemistry of Complex Equilibria*; Van Nostrand Reinhold Company: London, 1970.
- (48) Jankovics, H.; Pettinari, C.; Marchetti, F.; Kamu, E.; Nagy, L.; Troyanov, S.; Pellerito, L. Characterization of diorganotin(IV) complexes with captopril. The first crystallographically authenticated metal complex of this anti-hypertensive agent. *J. Inorg. Biochem.* **2003**, *97*, 370–376.
- (49) Yao, J.; Mo, Y. H.; Chen, J. M.; Lu, T. B. New approach to reduce the overhigh plasma concentration of captopril by the formation of zinc coordination polymer. *Cryst. Growth Des.* **2014**, *14*, 2599–2604.